RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Dr Reddy's Laboratories Stock

Dr Reddy's Laboratories Liabilities 2024

Dr Reddy's Laboratories Liabilities

106.09 B INR

Ticker

DRREDDY.NS

ISIN

INE089A01023

WKN

659157

In 2024, Dr Reddy's Laboratories's total liabilities amounted to 106.09 B INR, a 0.71% difference from the 105.35 B INR total liabilities in the previous year.

Dr Reddy's Laboratories Aktienanalyse

What does Dr Reddy's Laboratories do?

Dr. Reddy's Laboratories Ltd is an Indian pharmaceutical company that was founded in 1984 by Dr. K. Anji Reddy. The company started as a small laboratory in Hyderabad, India and quickly grew to become one of the leading global pharmaceutical companies. History The company began as a chemical research institute specializing in the development of high-quality generics and new drugs. Dr. Reddy's Laboratories was one of the first companies in India to begin manufacturing and exporting generics on a large scale. Today, the company operates in over 100 countries worldwide and employs over 21,000 people. Business Model The company's business model focuses on developing high-quality and affordable medications to improve the lives of patients worldwide. The company invests millions of dollars annually in research and development of new drugs to provide people with innovative and better treatment options. Various Divisions Dr. Reddy's Laboratories is divided into several business divisions, including: - Generics: A key business factor is generic production, including various dosages and forms of oral solid or liquid medications. - Biosimilars: Dr. Reddy's Laboratories has several biosimilars in its portfolio, including Epoetin alfa, Darbepoetin alfa, and Pegfilgastim, used for treating various diseases and conditions. - Specialty Products: The company also offers a variety of specialty products, particularly in the field of oncology. Products Over the years, Dr. Reddy's Laboratories has developed many innovative, high-quality, and affordable medications. Some of the company's most well-known products include: - Omez: A popular gastric medication used to treat heartburn and reflux. - Norflox: An antibiotic used to treat bacterial infections. - Reditux: A biosimilar of the antibody Rituximab used in cancer treatment. - Librium: A medication used for anxiety and depression. Conclusion Dr. Reddy's Laboratories is a global company specializing in the research, development, and manufacturing of innovative, high-quality, and affordable medications. The company has a long history in generic production and the manufacturing of specialty products and biosimilars. Through its research and development programs, the company constantly strives to meet the needs of patients and provide them with better healthcare. Dr Reddy's Laboratories ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Dr Reddy's Laboratories's Liabilities

Dr Reddy's Laboratories's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Dr Reddy's Laboratories's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Dr Reddy's Laboratories's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Dr Reddy's Laboratories's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Dr Reddy's Laboratories’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Dr Reddy's Laboratories stock

What is the level of liabilities of Dr Reddy's Laboratories this year?

Dr Reddy's Laboratories has a debt balance of 106.09 B INR this year.

What were the liabilities of Dr Reddy's Laboratories compared to the previous year?

The liabilities of Dr Reddy's Laboratories have increased by 0.71% increased compared to the previous year.

What are the consequences of high debt for investors of Dr Reddy's Laboratories?

High liabilities can pose a risk for investors of Dr Reddy's Laboratories, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Dr Reddy's Laboratories?

Low liabilities mean that Dr Reddy's Laboratories has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Dr Reddy's Laboratories affect the company?

An increase in liabilities of Dr Reddy's Laboratories can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Dr Reddy's Laboratories affect the company?

A decrease in the liabilities of Dr Reddy's Laboratories can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Dr Reddy's Laboratories?

Some factors that can influence the liabilities of Dr Reddy's Laboratories include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Dr Reddy's Laboratories so important for investors?

The liabilities of Dr Reddy's Laboratories are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Dr Reddy's Laboratories take to modify the liabilities?

To change its liabilities, Dr Reddy's Laboratories can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Dr Reddy's Laboratories pay?

Over the past 12 months, Dr Reddy's Laboratories paid a dividend of 40 INR . This corresponds to a dividend yield of about 0.59 %. For the coming 12 months, Dr Reddy's Laboratories is expected to pay a dividend of 43.54 INR.

What is the dividend yield of Dr Reddy's Laboratories?

The current dividend yield of Dr Reddy's Laboratories is 0.59 %.

When does Dr Reddy's Laboratories pay dividends?

Dr Reddy's Laboratories pays a quarterly dividend. This is distributed in the months of August, August, August, August.

How secure is the dividend of Dr Reddy's Laboratories?

Dr Reddy's Laboratories paid dividends every year for the past 0 years.

What is the dividend of Dr Reddy's Laboratories?

For the upcoming 12 months, dividends amounting to 43.54 INR are expected. This corresponds to a dividend yield of 0.65 %.

In which sector is Dr Reddy's Laboratories located?

Dr Reddy's Laboratories is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dr Reddy's Laboratories kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dr Reddy's Laboratories from 8/28/2024 amounting to 40 INR, you needed to have the stock in your portfolio before the ex-date on 7/16/2024.

When did Dr Reddy's Laboratories pay the last dividend?

The last dividend was paid out on 8/28/2024.

What was the dividend of Dr Reddy's Laboratories in the year 2023?

In the year 2023, Dr Reddy's Laboratories distributed 40 INR as dividends.

In which currency does Dr Reddy's Laboratories pay out the dividend?

The dividends of Dr Reddy's Laboratories are distributed in INR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Dr Reddy's Laboratories

Our stock analysis for Dr Reddy's Laboratories Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dr Reddy's Laboratories Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.